RxDoctor Payments Data

Victor Pinto-Plata, MD

Pulmonary Disease · Springfield, MANPI 1134114085

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,855 of the $11,500 with a category attached, or 77.0%. 13 manufacturers reported payments, led by Regeneron at 39.6% of the total. Reporting peaked in 2024 at $4,436 and has fallen 93.6% since, to $284 in 2025.

$11,500in general payments, 2019–2025

Across 51 payments — averaging $225.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$5K
  • Boehringer Ingelheim$2K
  • Astrazeneca UK Limited$2K
  • AstraZeneca$1K
  • GSK$1K
  • Novartis$258
  • plus $947 from 7 others
$48,454in research payments, 2019–2025

Across 12 payments — averaging $4037.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$48K
  • Sanofi$750

What the payments were for

  • Consulting fees$8,85577%
  • Travel & lodging$7116%
  • Food & beverage$1,88216%
  • Education$520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron7$4,551
Boehringer Ingelheim3$1,750
Astrazeneca UK Limited1$1,556
AstraZeneca9$1,294
GSK8$1,143
Novartis14$258
Fisher & Paykel Healthcare Inc1$254
Pulmonx Corporation2$195
Medical Graphics Corporation1$161
United Therapeutics Corporation1$150
Sanofi1$104
Pfizer2$58
Aero US Inc1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,500 in reported general payments places this provider in the 85th percentile of 482 pulmonary disease providers in Massachusetts.

See all pulmonary disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$89,046
Medicare patients
527
Services billed
1,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate22$291,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$81,632
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr64$38,270
Breo ElliptaFluticasone/Vilanterol73$33,821
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$32,385
Spiriva RespimatTiotropium Bromide35$23,505
Incruse ElliptaUmeclidinium Bromide32$14,905
Advair HfaFluticasone Propion/Salmeterol26$11,932
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$11,425
DuleraMometasone/Formoterol18$9,173
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$6,278
SymbicortBudesonide/Formoterol Fumarate15$5,709
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$3,966
Albuterol Sulfate HfaAlbuterol Sulfate95$3,589
Wixela InhubFluticasone Propion/Salmeterol39$3,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$1,750$326,22081 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$1,143$168,627261 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,294$38,09447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 482 pulmonary disease providers in Massachusetts.

Other pulmonary disease in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →